AI drug developer Recursion Pharmaceuticals has brought two more AI-focused companies with their own discovery platforms under its wing in an acquisition worth $87.5 million, the company announced today. Recursion is buying both companies, Cyclica and Valence, mostly in equity. The deals come as insiders predict a surge in biotech…
News
AZOVA Announces Cheryl Lee Eberting, M.D., Selected as an Ernst & Young Entrepreneur of The Year® 2023 Mountain West Award Winner
Entrepreneur of The Year Celebrates Ambitious Entrepreneurs Building A Better World ALPINE, Utah, July 12, 2023 /PRNewswire/ — Cheryl Lee Eberting, M.D., the founder and CEO of AZOVA, has been named as a winner of […]
News
STAT+: The FDA questions underlying Utah’s AI prescription pilot
Brittany Trang talks to STAT’s Mario Aguilar about Doctronic’s Utah AI pilot and issues facing AI doctors, in this AI Prognosis. Click here to view original post Click Here to Publish/Feature Your Company or Product […]
News
STAT+: Recursion CEO Chris Gibson out as company head after 12 years
Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI drug discovery. Click here to view original post Click Here to Publish/Feature Your […]
